Small Molecules

Halobetasol

Quality Solutions

Category: Dermatology



Authorized Distributor

USP can support your development and manufacturing activities on Halobetasol-based medicines with these existing and upcoming standards.

Official and Proposed Documentary Standards and Associated Physical Materials

MONOGRAPH 1

HALOBETASOL PROPIONATE Official as of 01-May-2020	
USP Halobetasol Propionate RS	USP-1302906
PHARMACEUTICAL ANALYTICAL IMPURITYIES* (PAI)	
USP 11-Propionate 21-Chloro Diflorasone PAI | *NEW*	USP-1A08130
USP 21-Acetate 17-Propionate Diflorasone PAI	USP-1A08140

INCLUDED GENERAL CHAPTERS

<11> USP REFERENCE STANDARDS
Official as of 01-Nov-2020

<197> SPECTROSCOPIC IDENTIFICATION TESTS
Official as of 01-Sep-2021

<281> RESIDUE ON IGNITION
Official as of 31-Dec-2012

<621> CHROMATOGRAPHY
Official as of 01-Oct-2023

<731> LOSS ON DRYING
Official as of 01-Nov-2020

<781> OPTICAL ROTATION
Official as of 01-Dec-2022

 # Pharmaceutical Analytical Impurities (PAI products) are released using a process developed by USP's subject matter experts. The release process is based on internal policies, standard operating procedures, and requirements as defined by USP's Quality Management System. USP is an ISO 9001:2015 certified facility. PAI products are different from official USP Reference Standards. PAI products are not required for compendial compliance.